1859
1859 is a technology company.
Active
Updated: ·
About
1859 is a technology company.
Financial History
Total Raised
N/A
Valuation
N/A
1859 is a technology company.
1859 is a technology company.
1859, Inc. is a biotechnology company that develops an AI-driven platform combining artificial intelligence with empirical screening data to accelerate small molecule drug discovery.[1][2][3] It builds a "design, build, test, learn" engine using next-generation DNA-encoded libraries and proprietary pico-scale screening to explore billions of molecular starting points, identify high-potential candidates, and optimize leads for therapeutics in oncology, immunology, and inflammation.[1][3] The platform serves pharmaceutical and biotech companies by generating proprietary datasets at scale to train robust AI/ML models, solving the challenge of slow, costly traditional drug discovery through rapid iteration and validation of predictions.[1][3] Founded in 2019 and headquartered in San Diego, 1859 raised a $40 million Series A in 2022, employs around 40-53 people, and shows growth through leadership expansions targeting high-value pipelines.[1][3]
1859 was founded in 2019 by Devon Cayer, Ph.D., and Andrew MacConnell, incubated at JLABS in San Diego.[1][2] Cayer, the initial CEO, brought expertise from The Scripps Research Institute where he invented DNA barcoding technologies, plus experience at Omniome (acquired by PacBio) and Singular Genomics in next-generation sequencing.[1] The idea emerged from combining chemical biology innovations with AI to industrialize medicine discovery, addressing limitations in computational-only or empirical-only methods by integrating massive-scale screening data.[1] Early traction included the 2022 Series A launch, highlighting their pico-scale platform's ability to test hundreds of thousands of predictions.[1] Leadership evolved with Sanket Agrawal as current CEO and additions like Consulting CSO Jeff Hager, Ph.D., and advisors Michael Howell, Ph.D., and Venkat Reddy, Ph.D., bringing oncology and immunology depth.[3]
1859 rides the AI-drug discovery wave, merging computational prediction with wet-lab validation amid a surge in biotech AI adoption to cut development timelines and costs.[1][3] Timing aligns with post-2022 funding recovery and advances in DNA-encoded libraries, enabling exploration of vast chemical spaces inaccessible to conventional screening.[1] Market forces favoring it include pharma's demand for faster small molecule leads in high-unmet-need areas like oncology and immunology, plus proximity to San Diego's ecosystem of research institutions and big pharma.[1][3] It influences the landscape by pioneering hybrid platforms that generate proprietary data flywheels, potentially setting standards for industrialized discovery and partnering with larger players to advance clinical assets.[3]
1859 is positioned to scale its pipeline into clinical stages, leveraging 2024+ expansions in oncology and immunology amid AI-biotech convergence.[3] Trends like multimodal AI training on empirical data and rising M&A in efficient discovery platforms will propel it, with potential for partnerships or further funding to validate leads.[1][3] Its influence may grow by disrupting siloed discovery models, delivering patient-impacting medicines faster—echoing its launch promise to industrialize new medicine via AI and scale.[1]